Dr. Charles A. Dinarello

Professor of Medicine in the Division of Infectious Diseases at the University of Colorado, Denver.  Dr. Dinarello is considered a founding father of cytokine biology and has received several awards from the medical community for his contributions.

Learn More

Treatment of Type 1 Diabetes

Omni Bio Pharmaceutical’s lead development program is evaluating an FDA approved, off-patent drug, Alpha-1 Antitrypsin ("AAT"), for the treatment of Type 1 diabetes.

Learn More

Alpha-1 Antitrypsin (AAT)

Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of bacterial and viral diseases, biohazards, diabetes and transplant rejection.

Learn More

Developing broad spectrum therapeutics using an existing FDA approved drug

Omni Bio Pharmaceutical, Inc. (OTC: OMBP) is an emerging biopharmaceutical company that has licensed therapies currently in development that have the potential to address unmet immunological diseases.  

Our core strategy is based on licensing issued and pending patents that cover new uses for an existing FDA-approved drug, Alpha-1 antitrypsin (AAT). We intend to leverage sponsored research, collaborations with existing AAT manufactures, and licensed patents for the development and commercialization of AAT in additional indications that exceed AAT’s current markets.

Learn more about alpha-1 antitrypsin (AAT)

Omni Bio Presents at Investor Conference

Omni Bio Pharmaceutical, Inc. presented at Noble Financial Capital Markets Eighth Annual Equity Conference on Wednesday, January 18th at the Hard Rock Hotel & Casino in Hollywood, Florida. Click on 'Learn more...' to watch the presentation and download the Powerpoint.

Learn more...

OmniBio Story

Watch this video to learn more about OmniBio's breakthrough research for Type 1 Diabetes.

Dr. Charles Dinarello discusses article he co-authored in Blood Magazine

From Our Blog

  1. OmniBio Chief Scientific Officer Co-Authors Paper on AAT Research Bob Ogden 17-Oct-2011

OmniBio proudly follows these fine groups and organizations

CU BDC
A1
CDF
JDRF
ADA